Nektar Therapeutics Unveils Impactful Data on Rezpegaldesleukin at 2026 AAD Meeting

Nektar Therapeutics (Nasdaq: NKTR) made a significant contribution to dermatological research by showcasing pivotal findings from its Phase 2b studies of Rezpegaldesleukin during the 2026 American Academy of Dermatology (AAD) Annual Meeting held in Denver, CO. This event gathered many leaders in dermatology to explore new frontiers in the treatment of skin conditions.

The company presented two main studies, with Dr. Raj Chovatiya, an expert associated with Rosalind Franklin University of Medicine and Science, leading discussions on the Phase 2b REZOLVE-AD study. This study involved 393 patients with moderate-to-severe atopic dermatitis—a condition characterized by chronic inflammation of the skin. Standard evaluation methods like the Eczema Area and Severity Index (EASI) were pivotal in measuring patient improvement throughout the 16-week duration of the trial.

The findings highlighted a statistically significant improvement in EASI scores among those treated with Rezpegaldesleukin compared to the placebo group. Notably, EASI-75 and EASI-90 metrics demonstrated high response rates, with patients showing at least a 75% and 90% improvement from their baseline scores, respectively. This consistency of results offers promising insights into the drug’s ability to cater to patients with varying degrees of disease severity.

Dr. Chovatiya remarked, "The consistency of EASI responses with Rezpegaldesleukin across baseline disease severity enhances its potential over traditional biologics, which often show lower efficacy in severely affected patients. Our novel agonist mechanism that promotes regulatory T cells might explain this breadth of response."

Nektar Therapeutics plans to expand their efforts with the upcoming Phase 3 ZENITH-AD program, aimed to launch in the second quarter of 2026, which will further explore the drug's effects in a larger patient population.

Another highlight from the AAD Meeting was presented by Dr. David Rosmarin, who shared findings from the REZOLVE-AA Phase 2b study targeting patients with severe-to-very-severe alopecia areata. This condition leads to hair loss caused by immune system attacks on hair follicles. Dr. Rosmarin reported that patients receiving higher doses of Rezpegaldesleukin exhibited a 28.2% mean reduction in their Severity of Alopecia Tool (SALT) scores, notably outperforming placebo both in percentage reduction and overall patient experience over the 36-week treatment period. "The clear activity of Rezpegaldesleukin in alopecia areata builds on prior results in atopic dermatitis, reinforcing its broader potential against T cell-driven inflammatory diseases," he noted.

The successful Phase 2b studies have ignited optimism regarding Rezpegaldesleukin’s role in restoring immune balance in various autoimmune conditions and highlight its potential as a first-in-class treatment for these challenges. Fast Track designations from the U.S. FDA in February and July of 2025 further endorse its development in atopic dermatitis and alopecia areata for patients who do not respond adequately to current therapies.

In summary, Nektar Therapeutics has taken a giant leap forward in the pharmaceutical landscape with Rezpegaldesleukin, which could change the narrative for patients suffering from chronic skin conditions. As they push forward with further clinical trials, the dermatology community is eager to see more comprehensive data on the therapeutic potential and safety profile of this innovative treatment.